机译:Daclatasvir和AsunaPrevir治疗后持续病毒学反应患者乙型肝炎病毒的晚期复发
Department of Gastroenterology and HepatologyMeijo HospitalNagoya Japan;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of Gastroenterology and HepatologyNagoya University Graduate School of MedicineNagoya;
Department of GastroenterologyOgaki Municipal HospitalOgaki Japan;
Department of GastroenterologyOgaki Municipal HospitalOgaki Japan;
Department of GastroenterologyYamashita HospitalIchinomiya Japan;
Department of Internal MedicineFujita Health UniversityNagoya Japan;
Department of Gastroenterology and HepatologyMeijo HospitalNagoya Japan;
direct‐acting antiviral; hepatitis C virus; late relapse; sustained virological response;
机译:Daclatasvir和AsunaPrevir治疗后持续病毒学反应患者乙型肝炎病毒的晚期复发
机译:达卡他韦和Asunaprevir联合治疗慢性丙型肝炎病毒基因型1b感染并肝硬化后24周病毒学应答持续缓解后复发
机译:丙肝病毒基因型lb的肝硬化患者用达克他韦+ Asunaprevir治疗17天后持续的病毒学应答,而聚乙二醇干扰素利巴韦林治疗无效
机译:HCV / HIV与Peginterferon Alfa-2a(40KD)(Pegasys〜R)加上利韦韦林(Copegus〜R)在杏试验期间HCV / HIV CONOMENT患者持续病毒学反应(SVR)的可预测性
机译:乙型肝炎病毒治疗患者体验,成功治疗对肝硬化的影响,以及持续的病毒性反应的含义
机译:达卡他韦和Asunaprevir联合治疗慢性丙型肝炎病毒基因型1b感染并伴有肝硬化的患者在24周后持续病毒学应答后出现晚期复发
机译:在没有基线NS5A多态性的丙型肝炎病毒基因型1b的老年和肝硬化患者中,对达卡他韦加Asunaprevir的高持续病毒学应答